BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 6, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 8, 2018
View Archived Issues
Enrollment ongoing in phase II/III trial of indoximod plus pembrolizumab or nivolumab in melanoma
Read More
Roswell Park Cancer Institute and NCI begin phase I trial of sirolimus plus vaccine therapy
Read More
Tosk set to begin proof-of-concept studies of TK-90
Read More
Generation Bio launches
Read More
Rocket and Inotek complete merger
Read More
Gossamer Bio launches with USD 100 million financing
Read More
Jiangsu Hengrui Medicine grants SHR-0302 rights to Arcutis for dermatology disorders
Read More
Stemline presents phase I/II data on SL-401 for myeloproliferative neoplasms
Read More
EMA gives orphan drug designation to Spruce Biosciences' SPR-001
Read More
Peregrine Pharmaceuticals changes name to Avid Bioservices
Read More
Momenta Pharmaceuticals announces topline data from phase I study of M-281
Read More
Northwestern University describes novel nitric oxide synthase inhibitors
Read More
MAKO study of squalamine with Lucentis in wet AMD misses primary endpoint
Read More
Institute of Organic Chemistry and Biochemistry and others patent 17-beta-HSD inhibitors
Read More
EMA accepts Evenity MAA in osteoporosis
Read More
New farnesoid X receptor modulators identified at Gilead
Read More
Alnylam and Sanofi to restructure RNAi therapeutics alliance
Read More
Rice University presents novel thailanstatin A derivatives
Read More
Cadent Therapeutics discovers new potassium channel modulators
Read More
FDA approves sBLA for Amgen's Xgeva
Read More
Final draft guidance by U.K.'s NICE recommends use of Strimvelis for ADA-SCID
Read More
Celgene agrees to acquire Impact Biomedicines
Read More
Rebiotix announces results of analysis of microbiome drug candidates
Read More
ADAR1-targeted therapy could ameliorate multiple myeloma patient outcomes
Read More
Takeda and Denali enter option and collaboration agreement in neurodegenerative diseases
Read More
Kala announces NDA acceptance for KPI-121 1%, phase III data for KPI-121 0.25%
Read More
Experiments reveal the potential of antibiotics for the treatment for colorectal cancer
Read More
Enanta conducts first-in-human study of EDP-938
Read More